The Trump rally has helped push the broad markets to new highs, and with earnings season just around the corner we can find out if this rally is fundamentally sound. But in the meantime there are a few other major companies reporting that might give us an idea of what to expect from their counterparts that report later this month and in February.
24/7 Wall St. has put together a peek of few companies that have just reported their most recent earnings. We have included the consensus estimates from Thomson Reuters as well as a recent trading history and consensus price target.
Before the markets opened on Thursday, Constellation Brands Inc. (NYSE: STZ) reported its fiscal third-quarter financial results. The company posted $1.96 in earnings per share (EPS) and $1.81 billion in revenue, versus consensus estimates from Thomson Reuters that called for EPS of $1.71 and $1.81 billion in revenue. The same period of last year reportedly had $1.42 in EPS and revenue of $1.64 billion.
Shares of Constellation Brands were trading down nearly 6% at $148.82 on Thursday, with a consensus analyst price target of $180.06 and a 52-week trading range of $130.23 to $173.55.
When Monsanto Co. (NYSE: MON) released its fiscal first-quarter earnings report before the markets opened, the company said that it had $0.21 in EPS and $2.65 billion in revenue. The consensus estimates had called for a net loss of $0.04 per share and revenue of $2.28 billion. The first quarter from last year had a net loss of $0.11 per share and $2.22 billion in revenue.
Monsanto shares were trading relatively flat at $105.72. The consensus price target is $119.50, and the 52-week range is $83.73 to $114.26.
Walgreens Boots Alliance Inc. (NASDAQ: WBA) posted its fiscal first-quarter results as well. The company said it had EPS of $1.10 and $28.5 billion in revenue. The consensus estimates were $1.09 in EPS and revenue of $29.24 billion. In the same period of last year, the retailer reported EPS of $1.03 and $29.03 billion in revenue.
Walgreens was last seen at $82.60, up fractionally, in a 52-week range of $71.50 to $88.00. The consensus price target is $93.15.